Skip to main content

Table 1 Clinical trials using gene expression analysis

From: Genomic and proteomic approaches for studying human cancer: Prospects for true patient-tailored therapy

Sponsor Principal investigator, centre Disease, application
European Organization for Research and Treatment of Cancer The Netherlands Cancer Institute, Amsterdam, The Netherlands Breast cancer, comparing van't Veer and van de Vijver prognostic signature to St Gallen criteria
Avon Foundation Daniel Haber, Massachusetts General Hospital, Boston, MA, USA Breast cancer, validating van't Veer and van de Vijver prognostic signature
Breast Cancer Research Foundation, Millennium Pharmaceuticals Lajos Pusztai, Anderson Cancer Center, Houston, TX, USA Breast cancer, validating own signature for predicting drug response
Millennium Pharmaceuticals Kenneth Anderson, Dana-Farber Cancer Center, Boston, MA, USA Multiple myeloma, validating own signature for response to Velcade
National Cancer Institute Jenny Chang, Baylor College of Medicine, Houston, TX, USA Breast cancer, validating own 90-gene prognostic signature
  1. Table adapted from Branca, M. (2003), Science Vol. 300, p. 238